Cooley LLP announced today that it represented NextBio, a Santa Clara-based leader in clinical and genomic informatics, in its acquisition by Illumina. Illumina is a leading developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function.
“With the addition of NextBio’s platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics solutions that accelerate the discovery of new associations between the human genome and disease, and ultimately, enable the application of those discoveries within healthcare,” states the Illumina company press release.
The Cooley team advising NextBio was led by partner Mehdi Khodadad and included partner Jennifer DiNucci, special counsel Brian Wheeler, and associates Robin Bennett and Alex Kassai. Critical support for the transaction was provided by partner Renee Deming and associate Justin Ho (compensation & benefits); partner Francis Fryscak (antitrust); partner Mark Windfeld-Hansen and associates Michael Baker and Keith Ranta (tax); of counsel Diane Savage, special counsel Chuck Schwab and associates Bryan Berman, Ian O’Neill and J.D. Moss (technology transactions); and senior counsel Lois Voelz and special counsel Ann Polus (employment).
Related Posts:
- Cooley Represents Quickoffice in its Sale to Google
- Cooley Represents BioMarin in $10 Million Acquisition of Zacharon
- Cooley Represents Solera Networks in Acquisition by Blue Coat
- Cooley Represents Epocrates in Its Sale to athenahealth
- Cooley Represents IDEV Technologies in Its Acquisition by Abbott Labs
